TY - JOUR
T1 - SWI/SNF complex, promising target in melanoma therapy
T2 - Snapshot view
AU - Mollapour Sisakht, Mahsa
AU - Amirkhani, Mohammad Amir
AU - Nilforoushzadeh, Mohammad Ali
N1 - Publisher Copyright:
Copyright © 2023 Mollapour Sisakht, Amirkhani and Nilforoushzadeh.
PY - 2023/2/9
Y1 - 2023/2/9
N2 - Therapeutic strategies based on epigenetic regulators are rapidly increasing in light of recent advances in discovering the role of epigenetic factors in response and sensitivity to therapy. Although loss-of-function mutations in genes encoding the SWItch/Sucrose NonFermentable (SWI/SNF) subunits play an important role in the occurrence of ~34% of melanomas, the potential of using inhibitors and synthetic lethality interactions between key subunits of the complex that play an important role in melanoma progression must be considered. Here, we discuss the importance of the clinical application of SWI/SNF subunits as a promising potential therapeutic in melanoma.
AB - Therapeutic strategies based on epigenetic regulators are rapidly increasing in light of recent advances in discovering the role of epigenetic factors in response and sensitivity to therapy. Although loss-of-function mutations in genes encoding the SWItch/Sucrose NonFermentable (SWI/SNF) subunits play an important role in the occurrence of ~34% of melanomas, the potential of using inhibitors and synthetic lethality interactions between key subunits of the complex that play an important role in melanoma progression must be considered. Here, we discuss the importance of the clinical application of SWI/SNF subunits as a promising potential therapeutic in melanoma.
UR - https://www.scopus.com/pages/publications/85148583701
U2 - 10.3389/fmed.2023.1096615
DO - 10.3389/fmed.2023.1096615
M3 - Review article
C2 - 36844227
AN - SCOPUS:85148583701
SN - 2296-858X
VL - 10
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 1096615
ER -